Boehringer Ingelheim Offers a Licence to Apotex to Export BI's patented product nevirapine to Developing Countries

27-Aug-2007

Boehringer Ingelheim has offered the Canadian generic pharmaceutical manufacturer Apotex Inc. a royalty free, voluntary licence to manufacture and export products containing nevirapine to Rwanda as requested by Apotex. Boehringer Ingelheim has also offered to extend the license to other developing countries as identified by the World Health Organization.

"This licence is one part of Boehringer Ingelheim's ongoing commitment to provide access to nevirapine in the developing world," states President and CEO of Boehringer Ingelheim (Canada) Ltd. Ian Mills. "For example, through its Viramune Donation Program for the Prevention of Mother-To-Child Transmission, Boehringer Ingelheim currently donates nevirapine to close to 60 countries to help prevent the transmission of HIV to new born children."

If Apotex accepts the voluntary licence, it will be free to manufacture product containing nevirapine for export to the developing world to help those patients suffering from HIV/AIDS. The terms of the licence offer are more favourable terms than those required under the access to medicines provisions of Canadian Legislation.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance